The company's financial results should remain strong for a while. Analysts expect earnings per share (EPS) to grow at an ...
Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...
The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...
Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...
Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a ...
A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...
Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of ...
A recent investigation by The New York Times revealed that two pharmaceutical companies, Eisai and Eli Lilly, withheld critical genetic risk information from volunteers during clinical trials for ...
A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...
Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...
Zacks.com on MSN2d
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?Eli Lilly and Company LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback